PRESS RELEASE 2021

In conjunction with C. Diff Infection Awareness Month, Ferring Pharmaceuticals launches new educational website Parsippany, New Jersey – November 11, 2021 – Ferring Pharmaceuticals and Rebiotix Inc., a Ferring Company, appreciate the support of New Jersey and Minnesota for officially recognizing ...

New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including those with comorbidities previously excluded from clinical trials Analysis adds to the consistent body of efficacy and safety evidence for RBX...

Parsippany, NJ – October 18, 2021 – Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress wi...

Ferring will present four abstracts at the congress including two oral and two poster presentations Ferring is demonstrating its leadership and furthering its commitment to researching innovative medicines for those looking to build their families Parsippany, NJ – October 14, 2021 – Ferring Pharm...

Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (r...

Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration o...

Fertility House Calls connects women and couples with personalized fertility care from the comfort of their own home. Service designed to reduce the emotional burden associated with the fertility journey Parsippany, NJ – September 15, 2021 – Ferring Pharmaceuticals announced today the...

Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile ( difficile) infection, adding to robust evidence of largest clinical development program in micro...

RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Ph...

For the first time ever, Ferring and Rebiotix, a Ferring Company, will present landmark Phase 3 efficacy and safety data from the PUNCHTM CD3 trial evaluating investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile (C. difficile) infection....

Teigen alongside RESOLVE: The National Infertility Association and Ferring Pharmaceuticals aim to change and amplify the fertility conversation by launching the Fertility Out Loud campaign during National Infertility Awareness Week (NIAW) (April 18-24, 2021). Fertility Out Loud encourages women a...